COVID-19 Spurs Transformation of Biopharma Industry Fundamentals
Share
COVID-19 Spurs Transformation of Biopharma Industry Fundamentals
By A. Kumar Singla, Managing Director, Sherwood Partners Inc. | Sherwood Healthcare Advisory Services
The most pronounced global economic and lifestyle shock in generations is currently in play. Following the initial tremor of COVID-19 that ripped across the globe over the past 18 months, the most urgent and widespread biopharmaceutical effort to develop therapeutics and vaccines the world has...
We hope you enjoyed your free content!
To continue, please become a TMA member.
Access the Journal of Corporate Renewal and other content in the Learning Link.
Become part of a global organization of turnaround and restructuring professionals with 54 Chapters and more than 400 events each year.
Build your personal brand and professional network with opportunities to connect, speak, lead, and win awards.
Kumar Singla is a managing director at Sherwood Partners Inc., based in the firm’s New York City office. He has experience in various roles, including in- and out-of-court restructurings, interim management, asset sale transactions, creditor negotiations, capital raising, and assignments for the benefit of creditors (ABCs). Singla has successfully restructured businesses and maximized values for numerous distressed assets in the life sciences, biotechnology, and other industry sectors. He holds a bachelor’s degree from Georgetown University and an MBA from the University of Michigan.
